Evaluation of FGFR inhibitor ASP5878 as a drug candidate for achondroplasia

Achondroplasia is caused by gain-of-function mutations in FGFR3 gene and leads to short-limb dwarfism. A stabilized analogue of C-type natriuretic peptide (CNP) is known to elongate bone by interacting with FGFR3 signals and thus is a promising drug candidate. However, it needs daily administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Tomonori, Kawamoto, Tatsuya, Iimori, Yuki, Takeshita, Nobuaki, Yamagishi, Yukiko, Nakamura, Hiroaki, Kamohara, Masazumi, Fujita, Kaori, Tanahashi, Masayuki, Tsumaki, Noriyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708468/
https://www.ncbi.nlm.nih.gov/pubmed/33262386
http://dx.doi.org/10.1038/s41598-020-77345-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708468/
https://www.ncbi.nlm.nih.gov/pubmed/33262386
http://dx.doi.org/10.1038/s41598-020-77345-y

Ejemplares similares